Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 33, Issue 8, Pages 1193-1198Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-010-0809-x
Keywords
Mitoxantrone; Folate-conjugated; Albumin nanoparticles
Categories
Funding
- Chongqing Natural Science Foundation [CSTC, 2008BB5397]
- Specialized Research Fund for the Doctoral Program of Higher Education of China [20020610092]
Ask authors/readers for more resources
Folic acid was covalently conjugated to bovine serum albumin nanoparticles (BSANP) to target the nanoparticles to SKOV3 cells expressing folate receptors. Mitoxantrone was incorporated into the folate-conjugated albumin nanoparticles, and the final nanoparticle size was 68 nm, as measured by a laser light scattering particle analyzer. The cytotoxic activity of mitoxantrone-loaded, folate-conjugated albumin nanoparticles (MTO-BSANP-folate), which was quantitated by (3)H-thymidine incorporation, was higher than mitoxantrone-loaded BSANP (MTO-BSANP) and MTO solution, and could be inhibited by free folic acid. MTO-BSANP-folate may be endocytosed via the folate receptor on the surface of SKOV3 cells. MTO-BSANP-folate also inhibited tumor growth better than the MTO-BSANP and MTO solution in vivo. These results indicate that folate-conjugated BSANP may have therapeutic potential as a vector for anticancer drugs in cancer chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available